The objectives of this project are to develop new agents for the chemoprevention and treatment of lung cancer. Lung cancers, especially those with a neuroendocrine phenotype, have specific cell surface receptors for a variety of neuropeptides. Binding of the peptide to the receptor activates a specific signal transduction pathway characterized by activation of G-proteins, phospholipase C, diacylglycerol, protein kinase C (PKC) and liberation of intracellular calcium by inositol trisphosphate. Activation of PKC and other proteins by the increase in [Ca2+]i leads to transcription of specific genes (jun, fos, myc) and proliferation. the activating peptides may be produced by tumor cells themselves (autocrine) and by pulmonary epithelial cells (paracrine). Cigarette smoke increases the production of these peptides. In a Syrian hamster model of lung cancer, chemical carcinogens present in cigarette smoke produced neuroendocrine hyperplasia, elevated levels of bombesin, calcitonin and other peptides and neuroendocrine cancers. We and others showed that the signal transduction pathway induced by multiple peptides could be blocked by using substance P derivatives which appear to down regulate multiple peptide receptors and by using B8509-035 which is a calcium/calmodulin/PKC antagonist. These compounds inhibited the growth of lung cancer cell lines in vitro at concentrations considerably below those which inhibit breast cancer cell line growth. B8509-035 was shown to prevent the development of neuroendocrine hyperplasia and neuroendocrine tumors in the Syrian hamster model. It was also shown to be non-toxic in animals and humans. Non-toxic doses in animals gave concentrations which were well above those which inhibited lung cancer cell line growth in vitro. In this proposal, we will perform in vitro studies to further elucidate the mechanism of action of these compounds, perform in vivo animal studies to allow these compounds to enter human clinical trials alone and in combination and perform initial phase I and phase II studies in human patients with supportive laboratory evaluations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058187-02
Application #
3774005
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
1993
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
Sakamoto, Mandy R; Honce, Justin M; Lindquist, Deborah L et al. (2018) Lorlatinib Salvages CNS Relapse in an ALK-Positive Non-Small-Cell Lung Cancer Patient Previously Treated With Crizotinib and High-Dose Brigatinib. Clin Lung Cancer :
McCoach, Caroline E; Blakely, Collin M; Banks, Kimberly C et al. (2018) Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer. Clin Cancer Res 24:2758-2770
Geraci, Mark W (2018) TARGETING THE PROSTACYCLIN/PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA AXIS IN LUNG CANCER CHEMOPREVENTION. Trans Am Clin Climatol Assoc 129:48-55
Robichaux, Jacqulyne P; Elamin, Yasir Y; Tan, Zhi et al. (2018) Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med 24:638-646
Kimball, Abigail K; Oko, Lauren M; Bullock, Bonnie L et al. (2018) A Beginner's Guide to Analyzing and Visualizing Mass Cytometry Data. J Immunol 200:3-22
Tippimanchai, Darinee D; Nolan, Kyle; Poczobutt, Joanna et al. (2018) Adenoviral vectors transduce alveolar macrophages in lung cancer models. Oncoimmunology 7:e1438105
DeHart, David N; Lemasters, John J; Maldonado, Eduardo N (2018) Erastin-Like Anti-Warburg Agents Prevent Mitochondrial Depolarization Induced by Free Tubulin and Decrease Lactate Formation in Cancer Cells. SLAS Discov 23:23-33
Ren, Shengxiang; Zhang, Shucai; Jiang, Tao et al. (2018) Early detection of lung cancer by using an autoantibody panel in Chinese population. Oncoimmunology 7:e1384108
Davies, Kurtis D; Le, Anh T; Sheren, Jamie et al. (2018) Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples. J Thorac Oncol 13:1474-1482
Iams, Wade T; Yu, Hui; Shyr, Yu et al. (2018) First-line Chemotherapy Responsiveness and Patterns of Metastatic Spread Identify Clinical Syndromes Present Within Advanced KRAS Mutant Non-Small-cell Lung Cancer With Different Prognostic Significance. Clin Lung Cancer 19:531-543

Showing the most recent 10 out of 435 publications